OPEN ACCESS Freely available online

HIV: Current Reserch

Commentary

Intersection of Tuberculosis and HIV: Strengthening Collaborative Efforts for Dual Control

Chris Edward*

Department of Biotechnology, Princeton University, Princeton, New Jersey, USA

DESCRIPTION

Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) are two major global health challenges that often coexist, making a harmful combination. The merging of these diseases presents significant clinical, public health, and socioeconomic implications.

The bidirectional relationship

Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) have a bidirectional relationship. HIV weakens the immune system by making individuals more susceptible to Tuberculosis (TB) infection.

Tuberculosis (TB) increases the development of HIV infection leading to higher viral loads and faster disease progression. This dual difficulty has severe consequences. The individuals infected with TB and HIV experience higher mortality rates, increased treatment complications and greater healthcare costs.

Challenges in diagnosis

Diagnosing TB in individuals with HIV presents significant challenges. The immune suppressed state caused by HIV infection can result in atypical clinical manifestations of TB, leading to delayed or missed diagnoses. Traditional diagnostic methods, such as sputum microscopy, may have lower sensitivity in HIV-positive individuals. The lack of sensitive and specific diagnostic tools specifically designed for individuals with both TB, HIV, and timely initiation of treatment.

Treatment complexities

The management of Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) coinfection requires integrated and coordinated efforts. Treatment hygienic for individuals with both diseases are complex and involving a delicate balance of Antiretroviral Therapy (ART) and anti-TB drugs.

The management of drug resistant Tuberculosis (TB) in the context of HIV further compounds the complexities requiring specialized care and access to second-line and novel anti-TB drugs.

Collaborative strategies for control

Strengthening prevention efforts: Prevention is the essential of Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) control. HIV testing should be routinely offered to all individuals diagnosed with TB and Tuberculosis (TB) screening should be an integral part of HIV care. Preventive therapy, such as Isoniazid Preventive Therapy (IPT), should be widely implemented among people living with HIV to reduce the risk of TB infection and disease progression.

Integrated service delivery: Integration of TB and HIV services is essential to ensure comprehensive care. Coordinated efforts between TB and HIV programs should be strengthened to enable simultaneous screening, diagnosis, and treatment initiation for both diseases. This integration can enhance access to services, improve treatment adherence, and reduce the burden on individuals seeking care.

Diagnostic innovations: Investment in research and development of improved diagnostic tools is critical. Efforts should focus on the development of diagnostic tests that can accurately detect TB in HIV-positive individuals, including those with low CD4 counts.

Access to treatment: Ensuring universal access to quality assured antiretroviral therapy and anti-TB drugs is vital. Efforts should be made to address barriers to treatment access, including affordability, availability, and healthcare system capacity

Research and innovation: The investment in research and innovation is crucial for developing new tools, strategies, and interventions. This includes the development of new drugs, shorter and more tolerable treatment and innovative approaches to prevent and manage drug-resistant TB in the context of HIV.

CONCLUSION

The intersection of TB and HIV presents a main challenge, requiring collaborative efforts at all levels. Strengthening prevention, promoting integrated service delivery, investing in diagnostic innovations, ensuring access to treatment and advancing research are all crucial components of an effective response.

Correspondence to: Chris Edward, Department of Biotechnology, Princeton University, Princeton, New Jersey, USA, E-mail: Chrised@zylker.com

Received: 02-May-2023, Manuscript No. HICR-23-25445; **Editor assigned:** 05-May-2023, PreQC No HICR-23-25445 (PQ); **Reviewed:** 19-May-2023, QC No. HICR-23-25445; **Revised:** 26-May-2023, Manuscript No. HICR-23-25445 (R); **Published:** 02-Jun-2023, DOI: 10.35248/2572-0805.23.8.231

Citation: Edward C (2023) Intersection of Tuberculosis and HIV: Strengthening Collaborative Efforts for Dual Control. HIV Curr Res. 8:231.